Europe Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Neutropenia Treatment Market
Market Report Description
The Europe Neutropenia Treatment Market would witness market growth of 6.2% CAGR during the forecast period (2020-2026). Neutropenia occurs when a person has low levels of neutrophils, a type of white blood cell. Neutrophils are formed in the bone marrow, which is the spongy tissue contained in larger bones, such as the vertebrae, ribs, and pelvis. White blood cells help the body battle infections. Neutrophils fight infection by removing toxic fungi, yeast, and bacteria that invade the body. People with neutropenia are at greater risk of contracting severe infections. Half of the cancer patients undergoing chemotherapy experience a level of neutropenia. Neutropenia is a common side effect in people with leukemia.
Growing cases of leukemia across the globe and a shift to the use of biosimilars from branded drugs in cancer-supporting treatment are driving the growth of the global neutropenia treatment market. Nevertheless, the high cost of treatment associated with neutropenia and the strict government regulations for product approval reduce the growth of the market. On the other hand, the increase in R&D activities for the development of new drugs creates new opportunities for market players in the coming years.
Novel treatments combined with growing cases of chemotherapy-induced neutropenia are one of the primary drivers of market growth. In addition, the novel drug delivery strategy also increases patient convenience, leading to greater adherence to the patient and thereby stimulates the growth of the market. Moreover, since cancer is a known cause of developing neutropenia, increasing cases of chemotherapy for cancer treatment will be a growth driver for the neutropenia treatment market.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Europe Neutropenia Treatment Market Analysis
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies and
- Online pharmacies
- Colony-stimulating factor
- Antifungals and
- Rest of Europe
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free